Mapping the Next Phase of Analytical Innovation for ADCs

Abstract

WuXi AppTec suggests “dynamic entities” require highly specialized analytical approaches

Get full access to this article

View all access options for this article.

References

Liu

Zhang

Zhou

, et al. (2018) Characterization of in vivo Biotransformations of Trastuzumab Emtansine (T-DM1) by High-Resolution Mass Spectrometry. mAbs. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204834/

Han

T. H.

, et al. (2013). CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. Clinical Pharmacology & Therapeutics. 94(6); 703–713. https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.116